|
US20070244120A1
(en)
*
|
2000-08-18 |
2007-10-18 |
Jacques Dumas |
Inhibition of raf kinase using substituted heterocyclic ureas
|
|
ATE538794T1
(de)
|
1999-01-13 |
2012-01-15 |
Bayer Healthcare Llc |
Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
OA12514A
(en)
|
1999-12-24 |
2006-05-29 |
Aventis Pharma Ltd |
Azaindoles.
|
|
DK1268472T3
(da)
|
2000-02-07 |
2004-12-06 |
Bristol Myers Squibb Co |
3-aminopyrazolinhibitorer af cyclinafhængige kinaser
|
|
EP1278749B1
(en)
|
2000-04-25 |
2005-01-26 |
Bristol-Myers Squibb Company |
USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
|
|
IL154016A0
(en)
*
|
2000-08-31 |
2003-07-31 |
Pfizer Prod Inc |
Pyrazole derivatives and their use as protein kinase inhibitors
|
|
AU2002215053A1
(en)
*
|
2000-11-27 |
2002-06-24 |
Pharmacia Italia S.P.A. |
Phenylacetamido- pyrazole derivatives and their use as antitumor agents
|
|
GB0115109D0
(en)
*
|
2001-06-21 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
|
JP4982685B2
(ja)
*
|
2001-12-03 |
2012-07-25 |
バイエル、ファーマシューテイカルズ、コーポレイション |
ヒトがんを処置するための他の細胞毒剤又は細胞増殖抑制剤と組合わせたアリール尿素化合物
|
|
US20050113283A1
(en)
*
|
2002-01-18 |
2005-05-26 |
David Solow-Cordero |
Methods of treating conditions associated with an EDG-4 receptor
|
|
MXPA04007832A
(es)
|
2002-02-11 |
2005-09-08 |
Bayer Pharmaceuticals Corp |
Aril-ureas con actividad inhibitoria de angiogenesis.
|
|
KR20030071029A
(ko)
*
|
2002-02-27 |
2003-09-03 |
주식회사 팜제니아 |
항암제 및 방사선 치료 증진제로서 유용한 조성물
|
|
US20030225089A1
(en)
*
|
2002-04-10 |
2003-12-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
|
|
DE10221052A1
(de)
*
|
2002-05-10 |
2003-12-04 |
Transmit Technologietransfer |
Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten
|
|
JP4751063B2
(ja)
*
|
2002-05-17 |
2011-08-17 |
ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ |
キナーゼ阻害剤として活性のアミノインダゾール誘導体、それらの調製方法、及びそれらを含む薬学的組成物
|
|
AU2003256755A1
(en)
|
2002-07-24 |
2004-02-09 |
Ptc Therapeutics, Inc. |
Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
|
|
MXPA05002493A
(es)
*
|
2002-09-05 |
2005-05-27 |
Neurosearch As |
Derivados de diarilurea y su uso como bloqueadores del canal del cloro.
|
|
WO2004033434A1
(en)
*
|
2002-10-09 |
2004-04-22 |
Pfizer Products Inc. |
Pyrazole compounds for treatment of neurodegenerative disorders
|
|
UA81790C2
(uk)
|
2002-12-19 |
2008-02-11 |
Фармация Италия С.П.А. |
Заміщені піролопіразольні похідні як інгібітори кінази
|
|
US7557129B2
(en)
|
2003-02-28 |
2009-07-07 |
Bayer Healthcare Llc |
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
|
|
GB0305426D0
(en)
*
|
2003-03-08 |
2003-04-16 |
Glaxo Group Ltd |
Novel compounds
|
|
WO2004113274A2
(en)
|
2003-05-20 |
2004-12-29 |
Bayer Pharmaceuticals Corporation |
Diaryl ureas with kinase inhibiting activity
|
|
PT1636236E
(pt)
|
2003-05-22 |
2013-12-16 |
Nerviano Medical Sciences Srl |
Derivados de pirazol-quinazolina, processo para sua preparação e sua utilização como inibidores de cinase
|
|
US7141568B2
(en)
|
2003-07-09 |
2006-11-28 |
Pfizer Italia S.R.L. |
Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
|
|
EA010485B1
(ru)
|
2003-07-23 |
2008-10-30 |
Байер Фамэсьютиклс Копэрейшн |
Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
|
|
TW200526204A
(en)
|
2004-02-03 |
2005-08-16 |
Pharmacia Italia Spa |
1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
|
|
US7244757B2
(en)
*
|
2004-04-01 |
2007-07-17 |
Pfizer Inc |
Pyrazole-amine compounds for the treatment of neurodegenerative disorders
|
|
EP1609789A1
(en)
*
|
2004-06-23 |
2005-12-28 |
Eli Lilly And Company |
Ureido-pyrazole derivatives and their use as kinase inhibitors
|
|
PL1778686T3
(pl)
*
|
2004-08-12 |
2009-04-30 |
Pfizer |
Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38
|
|
AR055831A1
(es)
|
2004-12-30 |
2007-09-12 |
Janssen Pharmaceutica Nv |
Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos
|
|
US20060183758A1
(en)
*
|
2005-02-17 |
2006-08-17 |
Cb Research And Development, Inc. |
Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
|
|
US7429800B2
(en)
*
|
2005-06-30 |
2008-09-30 |
Sabic Innovative Plastics Ip B.V. |
Molding composition and method, and molded article
|
|
WO2007009898A1
(en)
|
2005-07-19 |
2007-01-25 |
Nerviano Medical Sciences S.R.L. |
1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors
|
|
AR059826A1
(es)
*
|
2006-03-13 |
2008-04-30 |
Univ California |
Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
|
|
US20090118336A1
(en)
*
|
2006-05-03 |
2009-05-07 |
Laurent David |
Pyrazole derivatives and their use as pi3k inhibitors
|
|
AU2007312165A1
(en)
|
2006-10-21 |
2008-04-24 |
Abbott Gmbh & Co. Kg |
Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
|
|
TW200901974A
(en)
|
2007-01-16 |
2009-01-16 |
Wyeth Corp |
Compounds, compositions, and methods of making and using them
|
|
JP5675343B2
(ja)
*
|
2007-04-18 |
2015-02-25 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤としての尿素誘導体
|
|
AU2008263166A1
(en)
*
|
2007-05-25 |
2008-12-18 |
Janssen Pharmaceutica N.V. |
Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
|
|
EP2163541A1
(en)
*
|
2008-09-12 |
2010-03-17 |
Bayer Schering Pharma Aktiengesellschaft |
Piperazine derivatives for binding and imaging amyloid plaques and their use
|
|
CN102231983A
(zh)
*
|
2008-10-01 |
2011-11-02 |
北卡罗来纳大学查珀尔希尔分校 |
使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
|
|
US8461159B2
(en)
|
2008-11-25 |
2013-06-11 |
Jannsen Pharmaceutica BV |
Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
|
|
US8598356B2
(en)
*
|
2008-11-25 |
2013-12-03 |
Janssen Pharmaceutica Nv |
Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
|
|
EP3406260B1
(en)
|
2009-05-13 |
2020-09-23 |
The University of North Carolina at Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
|
WO2010141809A1
(en)
|
2009-06-05 |
2010-12-09 |
Janssen Pharmaceutica Nv |
Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
|
|
WO2010141817A1
(en)
|
2009-06-05 |
2010-12-09 |
Janssen Pharmaceutica Nv |
Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
|
|
EP2528604B1
(en)
|
2010-01-29 |
2017-11-22 |
The Regents of the University of California |
Acyl piperidine inhibitors of soluble epoxide hydrolase
|
|
UA108233C2
(uk)
|
2010-05-03 |
2015-04-10 |
|
Модулятори активності гідролази амідів жирних кислот
|
|
WO2012003476A2
(en)
*
|
2010-07-02 |
2012-01-05 |
Ventana Medical Systems, Inc. |
Hapten conjugates for target detection
|
|
AR082498A1
(es)
*
|
2010-08-20 |
2012-12-12 |
Gruenenthal Gmbh |
Derivados ciclicos de carboxamida y urea sustituidos como ligandos del receptor de vainiloide
|
|
CA2810954A1
(en)
|
2010-09-27 |
2012-04-05 |
Abbott Gmbh & Co. Kg |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
|
EP2640394A4
(en)
|
2010-11-17 |
2015-02-25 |
Univ North Carolina |
PROTECTION OF KIDNEY TISSUE FROM ISCHEMIA BY THE INHIBITION OF PROLEVERATIVE KINASES CDK4 AND CDK6
|
|
EP2614065B1
(en)
|
2010-12-17 |
2017-04-19 |
Nerviano Medical Sciences S.r.l. |
Substituted pyrazolo-quinazoline derivatives as kinase inhibitors
|
|
US9090592B2
(en)
|
2010-12-30 |
2015-07-28 |
AbbVie Deutschland GmbH & Co. KG |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
|
AU2012256237B2
(en)
|
2011-05-13 |
2017-01-05 |
Array Biopharma Inc. |
Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors
|
|
AR087701A1
(es)
*
|
2011-08-31 |
2014-04-09 |
Japan Tobacco Inc |
Derivados de pirazol con actividad inhibidora de sglt1
|
|
MY178262A
(en)
|
2012-11-13 |
2020-10-07 |
Array Biopharma Inc |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
WO2014078372A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
WO2014078408A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
US9969694B2
(en)
|
2012-11-13 |
2018-05-15 |
Array Biopharma Inc. |
N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
|
WO2014078378A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
US9809578B2
(en)
|
2012-11-13 |
2017-11-07 |
Array Biopharma Inc. |
Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
|
|
HRP20161613T1
(hr)
|
2012-11-13 |
2017-01-13 |
Array Biopharma, Inc. |
Tvari bicikličke ureje, tioureje, gvanidina i cijanogvanidina korisne za liječenje boli
|
|
US9981959B2
(en)
|
2012-11-13 |
2018-05-29 |
Array Biopharma Inc. |
Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
|
WO2014078328A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
|
US9790210B2
(en)
|
2012-11-13 |
2017-10-17 |
Array Biopharma Inc. |
N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
|
HK1222766A1
(zh)
|
2013-03-15 |
2017-07-14 |
G1治疗公司 |
高效的抗赘生剂和抗增生剂
|
|
DK2968290T3
(da)
|
2013-03-15 |
2019-11-25 |
G1 Therapeutics Inc |
Transient beskyttelse af normale celler under kemoterapi
|
|
WO2015161285A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
|
|
CA2949160C
(en)
|
2014-05-15 |
2023-03-21 |
Array Biopharma Inc. |
1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
|
|
WO2016040858A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
US20230092163A1
(en)
*
|
2019-06-14 |
2023-03-23 |
Ifm Due, Inc. |
Compounds and compositions for treating conditions associated with sting activity
|
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
|
WO2022135442A1
(zh)
*
|
2020-12-22 |
2022-06-30 |
上海拓界生物医药科技有限公司 |
Cdk2抑制剂及其制备方法
|
|
TW202235073A
(zh)
|
2021-01-08 |
2022-09-16 |
美商Ｉｆｍ Ｄｕｅ有限公司 |
用於治療與sting活性相關的病狀之化合物及組合物
|